Knight Therapeutics Inc.
Knight Therapeutics Inc. (KHTRF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
khtrf · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Knight Therapeutics Inc.You KHTRF | $635M | N/A | — | — |
 Allergy Therapeutics plc AGYTF | $655M | N/A | — | -$0.01 |
 Avacta Group Plc AVCTF | $437M | N/A | — | -$0.10 |
 BioInvent International AB (publ) BOVNF | $436M | N/A | — | -$5.05 |
 COLTENE Holding AG CLHLF | $456M | 19.50x | +76.2% | $2.49 |
 Cresco Labs Inc. CRLBF | $332M | N/A | — | -$0.42 |
 Hua Medicine (Shanghai) Ltd. HUMDF | $431M | 2.63x | -76.2% | $1.09 |
Industry Average 2 peers with valid PE | — | 11.07x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Knight Therapeutics Inc. (KHTRF) measures how much investors pay for each dollar of the company's trailing earnings. KHTRF's current PE ratio of N/A is calculated by dividing its stock price of $6.48 by its TTM earnings per share of —.
Frequently asked questions
KHTRF pe ratio · 6 questionsKHTRF's current PE ratio is N/A as of 2026-06-09, based on a stock price of $6.48 and TTM EPS of —. Data sourced from Financial Modeling Prep via KHTRF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Knight Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09